Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $8.2 million.

  • Seres Therapeutics' Profit After Tax fell 9075.88% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 12847.34%. This contributed to the annual value of -$125.8 million for FY2024, which is 3385.0% up from last year.
  • Latest data reveals that Seres Therapeutics reported Profit After Tax of $8.2 million as of Q3 2025, which was down 9075.88% from -$19.9 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Profit After Tax peaked at $88.8 million during Q3 2024, and registered a low of -$71.2 million during Q1 2023.
  • In the last 5 years, Seres Therapeutics' Profit After Tax had a median value of -$35.5 million in 2021 and averaged -$21.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 32529.06% in 2021, then tumbled by 18795.63% in 2022.
  • Quarter analysis of 5 years shows Seres Therapeutics' Profit After Tax stood at -$50.0 million in 2021, then tumbled by 37.59% to -$68.8 million in 2022, then surged by 49.54% to -$34.7 million in 2023, then soared by 54.96% to -$15.6 million in 2024, then skyrocketed by 152.47% to $8.2 million in 2025.
  • Its Profit After Tax was $8.2 million in Q3 2025, compared to -$19.9 million in Q2 2025 and $32.7 million in Q1 2025.